Kay Huh
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research
Most-Cited Works
- → Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer(2011)249 cited
- → Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies(2015)74 cited
- → Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors(2013)53 cited
- → A Prodrug Approach toward the Development of Water Soluble Fluoroquinolones and Structure−Activity Relationships of Quinoline-3-carboxylic Acids(2004)46 cited
- → Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials(2010)32 cited
- → Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model(2016)27 cited
- → Synthesis and Antibacterial Activity of Novel C12 Vinyl Ketolides(2006)22 cited
- → Abstract 3629: BLZ945, a selective c-fms (CSF-1R) kinase inhibitor for the suppression of tumor-induced osteolytic lesions in bone(2010)9 cited
- → Imidazo[1,2-a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors(2017)8 cited
- → Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K(2013)7 cited